CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- 4 Grant or award Chief Scientific Officer acquired 50,000 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 50,000 shares (grant or award)
- SC 13G Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- 4 Planned sale Chief Business Officer sold 40,000 shares at $16.18 ($647,200)
- 144 Insider Sale of Securities
- 4 Planned sale Chief Business Officer sold 40,000 shares at $14.09 ($563,600)
- SC 13G Stake Amended Statement of Ownership
- 144 Insider Sale of Securities
- 4 Planned sale Chief Business Officer sold 40,000 shares at an average $12.31 ($492,508)
- 144 Insider Sale of Securities
- 8-K/A Event Results of operations
- 8-K Event Acquisition or sale completed
- 4 Open-market sale President and CEO sold 4,272 shares at $9.24 ($39,473)
- 4 Open-market sale Chief Medical Officer sold 1,860 shares at $8.50 ($15,810)
- 4 Open-market sale Chief Legal Officer sold 1,400 shares at $8.50 ($11,900)
- 4 Open-market sale Chief Financial Officer sold 1,920 shares at $8.50 ($16,320)
Page 11 of 24 · 471 filings